Review ArticleSelective Immunophenotyping for Diagnosis of B-cell Neoplasms Immunohistochemistry and Flow Cytometry Strategies and ResultsBoyd, Scott D. MD, PhD*; Natkunam, Yasodha MD, PhD*; Allen, John R. BA†; Warnke, Roger A. MD*Author Information Departments of *Pathology †Oncology, Stanford University School of Medicine, Stanford, CA J.A. has been supported by NIH grant PO1CA034233. The authors declare no conflict of interest. Reprints: Scott D. Boyd, MD, PhD, Department of Pathology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305 (e-mail: [email protected]). Received February 25, 2012 Accepted May 2, 2012 Applied Immunohistochemistry & Molecular Morphology: March 2013 - Volume 21 - Issue 2 - p 116-131 doi: 10.1097/PAI.0b013e31825d550a Buy Metrics Abstract Determining the immunophenotype of hematologic malignancies is now an indispensable part of diagnostic classification, and can help to guide therapy, or to predict clinical outcome. Diagnostic workup should be guided by morphologic findings and evaluate clinically important markers, but ideally should avoid the use of overly broad panels of immunostains that can reveal incidental findings of uncertain significance and give rise to increased costs. Here, we outline our approach to diagnosis of B-cell neoplasms, combining histologic and clinical data with tailored panels of immunophenotyping reagents, in the context of the 2008 World Health Organization classification. We present data from cases seen at our institution from 2004 through 2008 using this approach, to provide a practical reference for findings seen in daily diagnostic practice. © 2013 Lippincott Williams & Wilkins, Inc.